AZGP1 and neoplasm: Consistent with decreased tumor burden at the experimental end point (Fig. 4B; Supplementary Fig. S5B), loss of ZAG resulted in decreased proliferation of MDA-MB-468 cells in vivo, though this difference did not reach significance (Fig. 4C).